Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients

被引:28
|
作者
Morizio, Paige [1 ]
Burkhart, Jena I. [2 ]
Ozawa, Sachiko [1 ,3 ]
机构
[1] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA
[2] UNC Med Ctr, Chapel Hill, NC USA
[3] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA
关键词
review article; osteoporosis; denosumab; bisphosphonates; cost-effectiveness; adherence; preference; WOMEN SUBOPTIMALLY ADHERENT; RANDOMIZED-OPEN-LABEL; LOW BONE MASS; POSTMENOPAUSAL OSTEOPOROSIS; UNITED-STATES; SATISFACTION; ALENDRONATE; MEDICATION; PREFERENCE; THERAPY;
D O I
10.1177/1060028018768808
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To assess the cost-effectiveness as well as adherence and patient preference for denosumab compared with oral bisphosphonates for the treatment of osteoporosis. Data Sources: Two comprehensive PubMed literature searches (from data inception to December 2017) were performed. The first search included the terms osteoporosis, denosumab, bisphosphonate, and adherence or persistence or compliance or preference. The search terms osteoporosis, denosumab, cost, and effectiveness were used in the second literature search. Additional references were included from reviewing literature citations. Study Selection and Data Extraction: All English-language clinical trials on adherence (as compliance and persistence) or patient preference for denosumab compared with oral bisphosphonates were evaluated. In addition, articles analyzing the cost-effectiveness of denosumab compared with generic alendronate were evaluated. Data Synthesis: Four studies that assessed patient preference showed positive outcomes for preference and satisfaction for subcutaneous use of denosumab every 6 months versus oral alendronate weekly, oral ibandronate monthly, or oral risedronate monthly. Three studies evaluated persistence and compliance and/or adherence and showed improved persistence and compliance rates with denosumab compared with bisphosphonate therapy. Twelve articles and 3 abstracts assessed cost-effectiveness of denosumab compared with generic alendronate. The majority of articles showed that denosumab was cost-effective, and even cost-saving in patients older than 75 years of age and those who have a history of previous fractures, lower bone mineral density T-scores, and more risk factors. Conclusions: Denosumab compared with oral bisphosphonates may improve patient preference and adherence as well as provide a cost-effective treatment strategy, especially among higher-risk and older adults with osteoporosis.
引用
收藏
页码:1031 / 1041
页数:11
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF DENOSUMAB COMPARED WITH ORAL BISPHOSPHONATES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROTIC WOMEN
    Hiligsmann, M.
    Reginster, J. Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 30 - 31
  • [2] Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US
    Parthan A.
    Kruse M.
    Yurgin N.
    Huang J.
    Viswanathan H.N.
    Taylor D.
    [J]. Applied Health Economics and Health Policy, 2013, 11 (5) : 485 - 497
  • [3] COST-EFFECTIVENESS OF INCREASING BISPHOSPHONATES ADHERENCE FOR OSTEOPOROSIS IN COMMUNITY PHARMACIES
    van Boven, J. F. M.
    Oosterhof, P.
    Hiddink, E. G.
    Stuurman-Bieze, A. G. G.
    Postma, M. J.
    Vegter, S.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A310 - A310
  • [4] COST-EFFECTIVENESS OF DENOSUMAB VERSUS ORAL BISPHOSPHONATES IN THE UNITED STATES FOR POST-MENOPAUSAL OSTEOPOROSIS (PMO)
    Parthan, A.
    Deflin, M. M.
    Yurgin, N.
    Huang, J.
    Taylor, D. C.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A38 - A38
  • [5] COST-EFFECTIVENESS OF DENOSUMAB IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) WOMEN IN MEXICO AT HIGH RISK OF FRACTURES AND INTOLERANT TO ORAL BISPHOSPHONATES
    Arocho, R.
    Rivera Hurtado, R.
    Salinas Escudero, G.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A225 - A225
  • [6] IS DENOSUMAB COST-EFFECTIVE COMPARED TO ORAL BISPHOSPHONATES FOR THE TREATMENT OF MALE OSTEOPOROSIS (MOP) IN SWEDEN?
    Parthan, A.
    Kruse, M. M.
    Agodoa, I
    Tao, C. Y.
    Silverman, S. L.
    Orwoll, E.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A223 - A223
  • [7] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Strom, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) : 967 - 982
  • [8] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    B. Jönsson
    O. Ström
    J. A. Eisman
    A. Papaioannou
    E. S. Siris
    A. Tosteson
    J. A. Kanis
    [J]. Osteoporosis International, 2011, 22 : 967 - 982
  • [9] Cost-Effectiveness of Oral Bisphosphonates for Osteoporosis at Different Ages and Levels of Life Expectancy
    Pham, Annalise N.
    Datta, Santanu K.
    Weber, Thomas J.
    Walter, Louise C.
    Colon-Emeric, Cathleen S.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 (09) : 1642 - 1649
  • [10] Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis
    B. Jönsson
    O. Ström
    J. A. Eisman
    A. Papaioannou
    E. S. Siris
    A. Tosteson
    J. A. Kanis
    [J]. Osteoporosis International, 2012, 23 : 2063 - 2065